Palo Alto CA, USA, 22 January 2025: Artificial, Inc (“Artificial”), a technology company providing cloud-based solutions to streamline laboratory operations and accelerate life science discoveries, today announced proof-of-concept data demonstrating the Artificial Platform’s workflow and model integration capabilities using NVIDIA BioNeMo, a generative AI platform for chemistry and biology.
NVIDIA BioNeMo is a platform for accelerating AI model development and deployment for computational drug discovery (1). In 2024, Artificial joined NVIDIA Inception, a free program designed to help startups evolve faster through cutting-edge technology, opportunities to connect with venture capitalists, and access to the latest technical resources. Through a proof-of-concept project, NVIDIA NIM microservices for AlphaFold2, MolMIM, and DiffDock were integrated with Artificial’s orchestration platform to facilitate advanced molecular screening.
The Artificial platform is designed to seamlessly integrate instruments, devices, people, and data systems, creating a holistic ecosystem tailored to modern laboratory needs. The platform's open API library and adapter modules allow for seamlessly incorporating the latest advances in AI/ML modeling, such as BioNeMo, into workflows. These integrations enhance operational efficiency by enabling sophisticated data analyses and iterative processes within orchestrated workflows. By aligning these models with existing lab systems, Artificial empowers scientific teams to leverage computational insights effectively, accelerating research timelines and elevating the precision of experimental outcomes.
The Company also announced it has received ISO 27001 and SOC 2 accreditations, marking another critical milestone in its mission to provide trusted and reliable solutions that support the adoption of the latest technological breakthroughs and preparation of the ‘labs of the future’. These globally recognized standards demonstrate the Company’s commitment to maintaining the highest levels of information security and data protection for its advanced model integration capabilities, which enable seamless incorporation of cutting-edge AI/machine learning models into laboratory workflows.
ISO 27001, the international standard for information security management, validates Artificial’s robust framework for protecting data and minimizing security risks throughout its Artificial Platform. SOC 2, a rigorous audit process, further recognizes the Company’s operational transparency and commitment to safeguarding sensitive information.
David Fuller, CEO, Artificial, Inc said: “To accelerate the development of gene therapies and life-saving drugs, or rapid pandemic response, the industry is increasingly recognizing the importance of adopting the latest breakthroughs in AI and machine learning – it is where the market is heading. These accreditations reflect our dedication to our customers’ security and compliance needs and give them confidence in our solutions as they go on this journey.”
He added: “We are excited by the work with NVIDIA to demonstrate our capabilities in space, to redefine what is possible in lab automation and provide the tools to enable researchers to accelerate scientific discoveries and optimize operations through the power of AI.”
Artificial will showcase its lab orchestration platform, including new features, at SLAS2025, taking place 25-29 January, in San Diego, CA. Booth 1427.
For more information about Artificial’s solutions, please visit: https://www.artificial.com/solutions/labops/
- Integrating NVIDIA BioNeMo NIM Microservices in Self-Driving Virtual Screening with Artificial, Inc.
About Artificial Inc.
Artificial Inc. digitizes the entire lab to accelerate the pace of life science discoveries with its cloud-based software platform. The Artificial Platform embraces the fundamental role of people in the scientific process so that every team has the software tools to make their digitization journey as simple and painless as possible. Lab Automation and Software teams utilize Artificial’s tooling to bring workflows to the cloud while leveraging an intuitive interface to orchestrate manual and automated protocols with a next-generation scheduler. Operators and scientists can access intuitive and interactive digital tools to guide them through all the manual tasks and streamline their digital experience. With the Artificial Platform, labs digitize their scientific ideas through automated execution while gathering a contextually complete complaint-ready data record in the cloud. Artificial helps labs with cell culture, NGS, drug discovery, and other common assays to create a closed-loop digital lab for more efficient scientific discovery.
Media contact:
Dr Ben Rutter
Zyme Communications
Tel: +44(0)7920 770 935
Email: [email protected]